a simple vaccine can be a powerful tool in fighting climate change
ArkeaBio™ is an agricultural science company developing a vaccine targeted to reduce livestock methane that is not only safe and cost-effective, but also realistic for large-scale execution using existing agronomic practices
livestock methane emissions total over 3 billion Tonnes per year of CO2 equivalents and are responsible for 6% of GHGs
Reducing methane emissions from the agricultural sector, including livestock, is imperative to mitigate the effects of climate change.
The world urgently needs solutions to mitigate GHGs.
Our vaccination-based approach allows for much-needed decarbonization of global meat and dairy products across multiple geographies, supporting greater sustainability in agriculture.
Vaccines can be quickly deployed worldwide at scale, providing ArkeaBio with an unmatched opportunity to make near-term global climate impact.
the recent convergence of vaccine development technologies and capabilities has created a unique and rapidly executable opportunity to significantly reduce GHGs
an anti-methanogen vaccine provides a singular technical solution for a distributed worldwide problem
Our vaccine solution will be safe, additive free, cost-effective, rapidly deployable and integrable at scale via existing agronomic practices.
Microbiological and bioinformatic analysis of both ArkeaBio and global Omic databases inform our vaccine target design allowing us to find targets unique to the methane producing organisms.
ArkeaBio continuously adapts our vaccine targets to both increase performance and ensure we stay ahead of the changing ruminal microbiome created by selective pressure, or any regional, feed, and seasonal based variations in the rumen.
Our knowledge of the rumen immune system, specific targets, and our field observations of vaccine performance allows us to tailor vaccine formulations to improve in-field performance.
Following vaccination, the immune response in the blood and saliva creates antibodies specific to methane producing microbes.
The saliva carries antibodies into the rumen where they neutralize the methane producing microbes.
The neutralizing antibodies adhere to the methane producing microbes reducing their ability to produce methane.
With a reduced population of methane producing microbes, the quantity of methane produced in the rumen and gut is reduced resulting in more climate friendly animal products. As an added benefit, feed energy that was previously lost through methane emissions is available to the animal rather than released into the atmosphere.
ArkeaBio is committed to understanding the mechanism by which our products function. Key to this is ensuring we have a broad measure of animal physiological responses and develop large enough data sets to allow simple validation of the benefits our products create.
our team is built on the foundation of strong scientific and commercial leaders
Matt Dunn has extensive experience in biochemistry and molecular biology, in particular nucleic acid protein engineering and evolution, to develop commercially relevant bioproducts. He leverages computational biology and high throughput screening strategies to accelerate the identification of biomolecules of interest, directly facilitating ArkeaBio’s vaccine development efforts. Matt is also versed in the development of comprehensive IP strategies for early-stage companies, including filing and prosecuting key patent applications for core technology. Matt holds a degree in genetics, cell, and developmental biology from UC Irvine and a PhD in molecular and cellular biology from Arizona State University.
Kristin Adolfsen is a microbiologist and engineer with experience in synthetic biology, metabolic modeling and engineering, and high-throughput screening. At ArkeaBio, she is leveraging her passion for high-throughput methodologies to develop antigen screening and validation technologies. Kristin holds a degree in chemical engineering from Penn State and a PhD in chemical engineering from Princeton University.
Lauren Fitch is a computational biologist with a passion for microbiology and synthetic biology. She has focused her career on the design and learn steps of the synthetic biology design-build-test-learn cycle, by building computational tools to design, analyze, and learn from genetically engineered microbes. At ArkeaBio, Lauren leads the antigen selection and design processes, as well as the development of next-generation sequencing pipelines to analyze data from ArkeaBio’s vaccine program. Lauren earned a BS in biology from Boston University and a PhD in molecular microbiology from Northeastern University.
Jim Spoonamore has experience with many aspects of biotechnologies including biosensor engineering, enzymology, assay development, high throughput screening, and early stage drug discovery. He holds a PhD in biochemistry and molecular biophysics from the University of Arizona.
Tom Overbay is a business development and technical consultant bringing nearly 35 years of experience to the international animal health industry. He founded Expedite Animal Health, a global company formed to discern opportunities in animal health then assist with product development across pharmaceuticals, biologicals, devices, and diagnostics. Tom holds his veterinary degree from the Virginia-Maryland Regional College of Veterinary Medicine and resides in Louisburg, Kansas.
Breakthrough Energy Ventures leads $12 million seed investment in ArkeaBio to develop and commercialize technology reducing on-farm methane emissions
Boston Real Estate Times
Freudenheim Partners relocates and expands ArkeaBio at 500 Rutherford Ave in Charlestown
Can a vaccine for cows slash methane emissions?